NewAmsterdam Pharma (NAMS.US) Announces Phase 2 Trial Results of CETP Inhibitor Under Development Effectively Reduces “Bad Cholesterol” Levels
The Zhitong Finance App learned that recently, NewAmsterdam Pharma (NAMS.US) announced the results of its Phase 2 trial to develop the CETP inhibitor Obicetrapib during the 2024 American College of Cardiology (ACC). Analysis showed that obicetrapib, as a single drug or in combination with ezetimibe, can effectively reduce low density lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia (dyslipidemia). NewAmsterdam also announced its associated Phase 3 key trial PRE
Zhitong FinanceApr 9 23:20 ET
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients With Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial ("CVOT") evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease ("ASCVD"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
GlobeNewswireApr 9 08:00 ET
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS)
TipRanksApr 2 08:30 ET
NewAmsterdam Pharma Announces Executive Leadership Changes
TipRanksApr 1 08:32 ET
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
We are privileged to welcome Juliette to our management team as CBO," said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.
GlobeNewswireApr 1 08:00 ET
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing
Johannes Jacob Pieter Kastelein, Director, Chief Scientific Officer, on March 26, 2024, sold 190,476 shares in Newamsterdam Pharma (NAMS) for $4,095,234. SEC Filing: https://www.sec.gov/Archives/edgar
MT NewswiresMar 27 16:41 ET
NewAmsterdam Pharma to Present New Analysis From the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination With Ezetimibe at 2024 American College of Cardiology Congress
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical co
GlobeNewswireMar 25 08:00 ET
NewAmsterdam Pharma Initiated at Sector Outperform by Scotiabank
NewAmsterdam Pharma Initiated at Sector Outperform by Scotiabank
Dow JonesMar 13 17:33 ET
Express News | Scotiabank Initiates Coverage On NewAmsterdam Pharma With Sector Outperform Rating, Announces Price Target of $35
Moomoo 24/7Mar 13 17:22 ET
Express News | NewAmsterdam Pharma Announced Dosing Of The First Patient And Initiation Of TANDEM Phase 3 Trial To Evaluate Obicetrapib And Ezetimibe FDC In Adult Patients With Heterozygous Familial Hypercholesterolemia And/Or Atherosclerotic Cardiovascular Disease
Moomoo 24/7Mar 12 08:13 ET
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients With HeFH And/or ASCVD
-- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination ("FDC") as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD ri
GlobeNewswireMar 12 08:00 ET
NewAmsterdam Pharma Updates Investor Presentation Online
TipRanksMar 4 08:22 ET
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) last week reported its latest annual results, which makes it a good time for investors to dive in and see if the business is performing in line with expe
Simply Wall StMar 3 07:20 ET
NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations
Yahoo FinanceMar 1 05:14 ET
NewAmsterdam Pharma Is Maintained at Outperform by RBC Capital
NewAmsterdam Pharma Is Maintained at Outperform by RBC Capital
Dow JonesFeb 29 12:19 ET
NewAmsterdam Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/29/2024 33.85% RBC Capital $25 → $31 Maintains Outperform 01/18/2024 29.53% Guggenheim → $30 Initiates
BenzingaFeb 29 12:08 ET
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk
NewAmsterdam Pharma (NAMS) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $20.04 to $34.15.
MT NewswiresFeb 29 07:55 ET
NewAmsterdam Pharma Reports FY Results
Seeking AlphaFeb 28 14:23 ET
NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress
Yahoo FinanceFeb 28 08:33 ET
NewAmsterdam Pharma Reports Full Year 2023 EPS $(2.15) Vs $(1.19) YoY; Revenue $14.1M Vs $102.7M YoY
Full Year 2023 Financial ResultsCash Position: As of December 31, 2023, NewAmsterdam recorded cash of $340.5 million, compared to $467.7 million as of December 31, 2022. The decrease is primarily due
BenzingaFeb 28 08:14 ET
No Data
No Data